INDSWFTLTD Intraday Analysis...

INDSWFTLTD Share Price

Open 5.75 Change Price %
High 5.75 1 Day 0.00 0.00
Low 5.60 1 Week 0.35 6.60
Close 5.65 1 Month -0.10 -1.74
Volume 13840 1 Year -1.30 -18.71
52 Week High 8.45
52 Week Low 3.85
INDSWFTLTD Important Levels
Resistance 2 5.79
Resistance 1 5.73
Pivot 5.67
Support 1 5.57
Support 2 5.51
NSE INDIA Most Active Stocks
SUZLON 19.45 6.58%
JPASSOCIAT 13.95 1.09%
IDEA 87.05 -2.08%
GMRINFRA 16.35 -0.30%
ANDHRABANK 57.25 -0.78%
IDFC 54.50 0.00%
UNITECH 5.65 3.67%
IBREALEST 87.25 8.66%
VEDL 274.50 2.12%
IFCI 29.90 1.18%
More..
NSE INDIA Top Gainers Stocks
PRECOT 88.90 19.97%
GOKEX 67.00 19.96%
COUNCODOS 3.65 19.67%
AUSTRAL 0.35 16.67%
NAKODA 0.40 14.29%
EKC 34.05 12.94%
RBL 1040.80 12.37%
SUNDRMBRAK 411.95 11.52%
IFGLREFRAC 224.10 11.27%
MUKTAARTS 104.30 10.60%
More..
NSE INDIA Top Losers Stocks
VKSPL 0.05 -50.00%
KSERASERA 0.15 -25.00%
VISESHINFO 0.15 -25.00%
SRGINFOTEC 0.25 -16.67%
BLUECHIP 0.30 -14.29%
REISIXTEN 0.40 -11.11%
GRAVITA 51.85 -9.90%
MAHLIFE 393.60 -9.64%
LAKSHMIEFL 55.15 -8.54%
VISUINTL 0.60 -7.69%
More..

Ind-Swift Limited (NSE: INDSWFTLTD)

INDSWFTLTD Technical Analysis 1.5
As on 30th Mar 2017 INDSWFTLTD Share Price closed @ 5.65 and we RECOMMEND Buy for LONG-TERM with Stoploss of 5.64 & Sell for SHORT-TERM with Stoploss of 5.68 we also expect STOCK to react on Following IMPORTANT LEVELS.
INDSWFTLTD Target for March
1st Target up-side 6.54
2nd Target up-side 7.09
3rd Target up-side 7.65
1st Target down-side 4.96
2nd Target down-side 4.41
3rd Target down-side 3.85
INDSWFTLTD Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 51.43 Sideways
MFI (14) MFI is 52.45 Sideways
CCI (20) CCI is 93.48 Sideways
WILLIAM %R (14) William %R is -50.00 Sideways
ADX (14) ADX is 18.05 Range Bound
PSAR Stoploss For Long Buy 5.08
10 Day Avg Volume Traded -18.92 % Less then 10 Day Average Volume
INDSWFTLTD Other Details
Segment EQ
Market Capital 0.00
Sector Pharmaceuticals
Industry
Offical website
INDSWFTLTD Address
INDSWFTLTD
N/A
INDSWFTLTD Latest News
Indian Parliament Stalls on Modi's Land-Acquisition Bill   Wall Street Journal   - 20th Mar 15
Financial Results & Limited Review for Dec 31, 2014 (Standalone)   Hindu Business Line   - 14th Feb 15
Ind Swift Lab Q3 loss narrows to Rs. 12 cr   Hindu Business Line   - 09th Feb 15
Ind-Swift Labs To Raise Funds From Strategic Investors   DealCurry   - 31st Jul 14
Ind-Swift in stake sale talks with US companies to raise Rs 200cr   Times of India   - 30th Jul 14
Deposit holders drag Ind-Swift to CLB   Business Standard   - 12th Sep 13
Piramal Healthcare in talks to buy Ind-Swift Lab: Report   India Today   - 04th Sep 12
Punjab National Bank forwards Ind-Swift case for debt recast   Hindu Business Line   - 27th Aug 12
Ind-Swift Labs gets USFDA approval for 5 APIs for its Derabassi facility   Moneylife Personal Finance site and magazine   - 10th Apr 12
Ind Swift Lab gets Australia's nod for its Dera Bassi plant   Economic Times   - 23rd Sep 11
Interactive Technical Analysis Chart Ind-Swift Limited ( INDSWFTLTD NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ind-Swift Limited
INDSWFTLTD Business Profile
Ind Swift was incorporated as a public sector unit in Jun. 6, 1986. Chandigarh-based Ind-Swift is the flagship company of India based Ind Swift Group, a pharmaceutical company. Various categories of products manufactured by the company include analgesics, anti-diabetics, anti-infective, cardiovascular drugs, nutritional and supplementary drugs. Manufacturing facilities of the company are located in Himachal Pradesh, Haryana and Jammu and Kashm. In the year 2002 the company achieved ISO 9001-2000 Certification. It also attained leading position in the world in the products like Clarithromycin granules. The company exports to almost 40 countries in the world and has set up eleven representative offices worldwide. In the 2004 the company launched the first oversees office in New Jersey, US. It also launched combination of Nitazoxanide and Ofloxacin, with the brand name Netazox-OF, first time in Asia. The current market capitalization stands at Rs 27.71 crore. The company has reported a standalone sales of Rs 139.17 crore and a Net Loss of Rs 41.99 crore for the quarter ended June 2013. The company management includes S R Mehta - Chairman, N R Munjal - Vice Chairman, Gopal Munjal - Managing Director & CEO, V R Mehta - Joint Managing Director, Himanshu Jain - Director, Rishav Mehta - Director, K M S Nambiar - Director, R S Bedi - Director, H P S Chawla - Director, S K Mathur - Director, S P Sharma - Independent Director, Atul Saxena - Nominee Director. The Registered office is at 781, Industrial Area - II , Chandigarh, Chandigarh - 160002.